{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:47:37Z","timestamp":1794278857310,"version":"4.9.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ijantimicag.2023.106741","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T02:29:12Z","timestamp":1675218552000},"page":"106741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["In-vitro activity of ceftolozane\/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016 and 2019 in China"],"prefix":"10.1016","volume":"61","author":[{"given":"Wei","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PeiYao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YingChun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"QiWen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106741_bib0001","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1099\/mic.0.000860","article-title":"Microbe profile: Pseudomonas aeruginosa: opportunistic pathogen and lab rat","volume":"166","author":"Diggle","year":"2020","journal-title":"Microbiology"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0002","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1093\/jac\/dky279","article-title":"Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015\u201317)","volume":"73","author":"Sader","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176774","article-title":"Molecular epidemiological survey of bacteremia by multidrug resistant Pseudomonas aeruginosa: the relevance of intrinsic resistance mechanisms","volume":"12","author":"Dantas","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3329\/bjmm.v9i2.31348","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria and antimicrobial therapy in combination","volume":"9","author":"Shamsuzzaman","year":"2017","journal-title":"Bangladesh J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0005","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1093\/cid\/ciz824","article-title":"Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria","volume":"69","author":"Nordmann","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0006","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13104-021-05503-0","article-title":"A retrospective cross-sectional survey on nosocomial bacterial infections and their antimicrobial susceptibility patterns in hospitalized patients in northwest of Iran","volume":"14","author":"Sadeghi","year":"2021","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0007","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0008","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/jcm9010275","article-title":"Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia","volume":"9","author":"Jean","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0009","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0010","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1016\/j.jmb.2020.07.021","article-title":"Current knowledge and future directions in developing strategies to combat Pseudomonas aeruginosa infection","volume":"432","author":"Dolan","year":"2020","journal-title":"J Mol Biol"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0011","doi-asserted-by":"crossref","first-page":"e00595","DOI":"10.1128\/JB.00595-18","article-title":"Genomic and phenotypic diversity among ten laboratory isolates of Pseudomonas aeruginosa PAO1","volume":"201","author":"Chandler","year":"2019","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0012","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/phar.1609","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/beta-lactamase inhibitor combination","volume":"35","author":"Cho","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0013","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/AAC.00860-06","article-title":"In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa","volume":"51","author":"Takeda","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0014","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/AAC.00912-09","article-title":"In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance","volume":"54","author":"Bulik","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0015","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1016\/j.bmcl.2008.07.085","article-title":"Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205","volume":"18","author":"Toda","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0016","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/CMR.00037-09","article-title":"Three decades of beta-lactamase inhibitors","volume":"23","author":"Drawz","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0017","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/jac\/25.2.199","article-title":"Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I \u03b2-lactamases","volume":"25","author":"Akova","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0018","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bjid.2017.06.008","article-title":"Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013\u20132015)","volume":"21","author":"Pfaller","year":"2017","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0019","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/14787210.2016.1233060","article-title":"What is the role of the new beta-lactam\/beta-lactamase inhibitors ceftolozane\/tazobactam and ceftazidime\/avibactam?","volume":"14","author":"Gentile","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0020","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2021"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0021","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0022","doi-asserted-by":"crossref","first-page":"e00181","DOI":"10.1128\/CMR.00181-19","article-title":"Antimicrobial resistance in ESKAPE pathogens","volume":"33","author":"De Oliveira","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0023","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1093\/cid\/ciy657","article-title":"Current status and trends of antibacterial resistance in China","volume":"67","author":"Hu","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0024","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.ajic.2014.08.006","article-title":"Multidrug-resistant Pseudomonas aeruginosa infections pose growing threat to health care-associated infection control in the hospitals of Southern China: a case\u2013control surveillance study","volume":"42","author":"Peng","year":"2014","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0025","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.3389\/fmicb.2019.02240","article-title":"Crisis of antimicrobial resistance in China: now and the Future","volume":"10","author":"Qu","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0026","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011\u20132012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0027","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ijantimicag.2014.01.032","article-title":"Ceftolozane\/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)","volume":"43","author":"Farrell","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0028","doi-asserted-by":"crossref","first-page":"e02431","DOI":"10.1128\/AAC.02431-18","article-title":"Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the in vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa","volume":"63","author":"Yin","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0029","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ijantimicag.2019.02.004","article-title":"Activity of ceftolozane\/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: the SUPERIOR multicentre study","volume":"53","author":"Garcia-Fernandez","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0030","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.3201\/eid2510.181699","article-title":"Risk factors for carbapenem-resistant Pseudomonas aeruginosa, Zhejiang Province, China","volume":"25","author":"Hu","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0031","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1128\/AAC.01104-09","article-title":"Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients","volume":"54","author":"Moya","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0032","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40265-015-0524-5","article-title":"Ceftolozane\/tazobactam: a review in complicated intra-abdominal and urinary tract infections","volume":"76","author":"Scott","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0033","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13756-019-0499-1","article-title":"Shifting trends and age distribution of ESKAPEEc resistance in bloodstream infection, Southwest China, 2012\u20132017","volume":"8","author":"Yang","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0034","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.micpath.2017.06.018","article-title":"A 16-year retrospective surveillance report on the pathogenic features and antimicrobial susceptibility of Pseudomonas aeruginosa isolates from FAHJU in Guangzhou representative of Southern China","volume":"110","author":"Xie","year":"2017","journal-title":"Microb Pathog"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0035","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/clinids\/24.2.211","article-title":"Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit","volume":"24","author":"Archibald","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106741_bib0036","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01190-2017","article-title":"Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients","volume":"52","author":"Restrepo","year":"2018","journal-title":"Eur Respir J"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923000298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923000298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:44:33Z","timestamp":1760377473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923000298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0924857923000298"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106741","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In-vitro activity of ceftolozane\/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016 and 2019 in China","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106741"}}